Heterobifunctional MDM2 Degraders for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new agents, such as small molecules, to effectively disrupt or prevent the MDM2-p53 interaction for treating cancer and other diseases, as existing therapies are inadequate in addressing the MDM2-p53 axis effectively.
Innovation Solution
Development of heterobifunctional compounds represented by Formulas I and II, which act as MDM2 protein degraders, administered to subjects to treat conditions like cancer, chronic autoimmune disorders, and viral infections by degrading MDM2 proteins, thereby inhibiting their activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small-molecule inhibitors targeting the p53-MDM2 interaction are used, then p53 activity is restored, but the therapeutic effectiveness is insufficient
Solution Approach 1:
The patent introduces heterobifunctional compounds as intermediaries that bridge the small-molecule inhibitor and the MDM2 protein. These compounds contain two functional moieties: one that binds to p53 and another that binds to MDM2, thereby mediating the disruption of the MDM2-p53 interaction more effectively than direct inhibitors alone
Solution Approach 2:
The invention employs composite molecular structures combining different functional elements in a single heterobifunctional compound. The compound integrates a p53-binding domain and an MDM2-targeting domain, creating a composite agent that simultaneously addresses multiple aspects of the MDM2-p53 axis pathology
2Productivity
If MDM2 protein levels are reduced through degradation, then cell proliferation is inhibited, but the mechanism requires novel heterobifunctional compound development
Solution Approach 1:
The heterobifunctional compound is segmented into distinct functional modules: a p53-interaction domain and an MDM2-targeting domain connected by a linker. This segmentation allows each module to perform its specific function while maintaining overall compound functionality, making the complex structure manageable and designable
Solution Approach 2:
The linker region acts as an intermediary element connecting the p53-binding moiety and the MDM2-targeting moiety. This intermediary component enables the two functional domains to work together while maintaining appropriate spatial orientation and binding affinity
Data Source
AI summary
The present disclosure provides compounds represented by Formula I:wherein R1a, R1b, R2a, R2b, R3a, R3b, R4, A, L, X, Y, and Z are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat cancer or any other disease, condition, or disorder that is responsive to degradation of MDM2 protein.